Overview

Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer

Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
Multicenter, prospective, randomized studies.Evaluation of the sensitivity to different chemotherapy regimens in platinum-partial sensitive recurrent ovarian cancer based on 11 gene tests of homologous recombination pathway.
Phase:
Phase 3
Details
Lead Sponsor:
Hunan Cancer Hospital
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Doxorubicin
Liposomal doxorubicin
Paclitaxel